Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
Hamzah Abu‐Sbeih(The University of Texas MD Anderson Cancer Center), Yinghong Wang(Hangzhou Center for Disease Control and Prevention), Mazen Alasadi(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Phillip S. Ge(The University of Texas MD Anderson Cancer Center), Manoop S. Bhutani(Medical University of South Carolina), Cynthia N. Tran(Baylor College of Medicine), Aung Naing(The University of Texas MD Anderson Cancer Center)
Cited by 51
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484